BioTuesdays

Category - Markets

PTC Therapeutics

WB starts PTC Therapeutics at MP

William Blair initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “market perform” rating, citing a possibly tough road ahead for approval of the company’s ataluren in the U.S. The stock closed at $17.72 on Aug...

CymaBay

Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22. CymaBay is currently developing seladelpar for the lead...

Wave Life Sciences

Mizuho starts Wave Life Sciences at buy

Mizuho Securities initiated coverage of Wave Life Sciences (NASDAQ:WVE) with a “buy” rating and price target of $34. The stock closed at $17.50 on August 16. Analyst Salim Syed writes that Wave is an idea-rich, nucleic...

HCW starts Alphatec at buy

H.C. Wainwright initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $4 price target, calling the company a “turnaround story in a high growth market.” The stock closed at $1.68 on August 11...

Novavax Logo

Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and...

AIT Therapeutics

Ladenburg starts AIT Therapeutics at buy

Ladenburg Thalmann launched coverage of AIT Therapeutics (NASDAQ:AITB) with a “buy” rating and $17 price target. The stock closed at $5.50 on Aug. 4. AIT is currently developing its proprietary nitric oxide (NOx) to...

Molecular Templates

Ladenburg starts Molecular Templates at buy

Ladenburg Thalmann initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $10.00 price target. The stock closed at $5.50 on August 2. “We believe the company’s Engineered Toxin Bodies (ETBs)...

STAAR Surgical

Canaccord ups STAAR price target to $11

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $11 from $9 following the company’s second quarter results. The stock closed at $10.55 on August 2. Analyst Jason Mills, who said he was...

Apollo Endosurgery

Roth starts Apollo at buy

Roth Capital Partners initiated coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and target price of $10. The stock closed at $6.21 on August 2. “We believe Apollo is an attractive ‘masked growth’ Med...